| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Feb, 2026 |
| Sales | 9,360 | 2,530 | 0 | 0 | 0 |
| Sales Growth | +269.96% | unch | unch | unch | unch |
| Net Income | -9,040 | -7,940 | -8,150 | -6,320 | 0 |
| Net Income Growth | -13.85% | +2.58% | -28.96% | unch | unch |
Bioaffinity Technologies Inc
(BIAF)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO.
Fiscal Year End Date: 12/31